8-K: Inotiv Reports Strong Preliminary Q4, FY25 Revenue

Inotiv, Inc. announced preliminary unaudited financial results for the fourth quarter and full fiscal year 2025, showing revenue growth and strong contract awards in its DSA services business.

Summary

• Preliminary Q4 FY 2025 revenue is expected to be between $137.5 million and $138.5 million.
• Preliminary full year FY 2025 revenue is expected to be between $512.5 million and $513.5 million.
• The Discovery and Safety Assessment (DSA) services business achieved an anticipated book-to-bill ratio of approximately 1.08x for Q4 FY 2025 and 1.05x for the full fiscal year.
• DSA backlog is anticipated to be approximately $138.0 million at September 30, 2025, an increase from $129.9 million at September 30, 2024, and $134.3 million at June 30, 2025.
• The company's CEO noted strong sequential growth in DSA contract awards for Q4, up 60% over the prior year period.
• Full audited results for Q4 and FY 2025 are expected in early December.

Sentiment

Score: 7

Explanation: The preliminary results show strong revenue growth and positive indicators like increasing backlog and book-to-bill ratios, which are favorable. However, the results are unaudited and subject to change, and the company highlights numerous significant risks in its forward-looking statements, tempering overall sentiment.

Positives

• Preliminary Q4 FY 2025 revenue of $137.5 million to $138.5 million is in line with expectations and an improvement over the prior year period.
• Strong contract awards in the Discovery and Safety Assessment (DSA) services business, growing sequentially in Q4 and up 60% over the same period last year.
• DSA services business achieved a healthy book-to-bill ratio of approximately 1.08x for Q4 FY 2025 and 1.05x for the full fiscal year.
• DSA backlog increased to approximately $138.0 million at September 30, 2025, from $129.9 million a year prior and $134.3 million at June 30, 2025, indicating future revenue visibility.

Negatives

• The results are preliminary and unaudited, subject to change upon completion of year-end accounting and audit procedures.
• The independent registered public accounting firm does not express an opinion or any other form of assurance on these preliminary figures.

Risks

• Trends in the demand for the company's services and products.
• Trends in the industries that consume the company's services and products.
• Market and company-specific impacts of non-human primate supply and demand matters.
• Compliance with the Resolution Agreement and Plea Agreement, including expected impacts on the company related to the compliance plan and compliance monitor, and the expected amounts, timing, and expense treatment of cash payments and other investments thereunder.
• Ability to service outstanding indebtedness and to comply or regain compliance with financial covenants.
• Current and forecasted cash position.
• Ability to make capital expenditures, fund operations, and satisfy obligations.
• Ability to manage recurring and unusual costs.
• Ability to execute on and realize the expected benefits related to restructuring and site optimization plans.
• Expectations regarding the volume of new bookings, pre-sales, pricing, cost savings initiatives, expansion of services, operating income or losses, and liquidity.
• Ability to effectively fill recent expanded capacity or any future expansion or acquisition initiatives.
• Ability to develop and build infrastructure and teams to manage growth and projects.
• Ability to continue to retain and hire key talent.
• Ability to market services and products under its corporate name and relevant brand names.
• Ability to develop new services and products.
• Ability to negotiate amendments to the Credit Agreement or obtain waivers related to the financial covenants defined within the Credit Agreement.
• Potential outcome of litigation against the company, including any settlement and amounts accrued or recoverable.
• Risks related to the recent cybersecurity incident impacting the company.
• Impact of macroeconomic factors, including but not limited to tariffs.

Future Outlook

The company anticipates reporting its full audited results for the fourth quarter and fiscal year 2025 in early December. Management expects continued execution on financial goals and strong contract awards in its Discovery and Safety Assessment services business.

Management Comments

• During the fourth quarter of fiscal 2025, we continued to execute on the financial goals we discussed during our investor day in May.
• We have continued to see strong contract awards in our Discovery and Safety Assessment ('DSA') services business, which grew sequentially in the fourth quarter and were up 60% over the same period last year.
• We anticipate that consolidated revenue for the fourth quarter will be in a range of $137.5 million to $138.5 million, in line with our expectations and an improvement over the prior year period.
• We look forward to reporting our full results for the fourth quarter and fiscal year 2025 in early December.

Industry Context

Inotiv operates as a leading contract research organization (CRO) specializing in nonclinical and analytical drug discovery and development services, as well as research models. The reported preliminary results, particularly the strong book-to-bill ratios and backlog growth in DSA services, suggest a healthy demand environment within the broader pharmaceutical and biotechnology R&D sector, where companies increasingly outsource preclinical development to specialized CROs to enhance efficiency and accelerate drug pipelines.

Comparison to Industry Standards

• The filing does not provide specific comparable company or project data to assess against global benchmarks.
• A book-to-bill ratio above 1.0x (1.08x for Q4 DSA, 1.05x for FY25 DSA) is generally considered positive in the CRO industry, indicating that new business is outpacing revenue recognition, which is a healthy sign for future growth.
• Without specific industry averages for Q4 2025, a direct comparison to peers like Charles River Laboratories (CRL) or LabCorp (LH) for the same period is not possible from this filing alone.

Stakeholder Impact

• Shareholders: Positive preliminary financial results and growth in backlog could lead to increased investor confidence and potential share price appreciation. However, the preliminary nature of the results and the extensive list of risks could introduce volatility.
• Customers: Strong contract awards and increased backlog suggest continued demand for Inotiv's nonclinical and analytical drug discovery and development services, indicating ongoing customer trust and engagement.
• Employees: Continued growth and execution on financial goals may provide job stability and potential opportunities, though restructuring and site optimization plans (mentioned as a risk) could impact some employees.

Next Steps

• Robert Leasure, Jr. to present at the Jefferies Global Healthcare Conference on November 18, 2025.
• Release of full audited results for the fourth quarter and fiscal year 2025 in early December.
• Completion of the company's year-end accounting and financial reporting and audit procedures.

Key Dates

Recommendation

The preliminary results indicate positive momentum with revenue growth, strong book-to-bill ratios, and increasing backlog, particularly in the DSA segment. This suggests healthy operational performance and demand for Inotiv's services. However, these are unaudited preliminary figures, subject to change, and the company faces a comprehensive list of significant risks, including compliance with past agreements, financial covenants, and macroeconomic factors. Given the positive operational indicators balanced against the inherent uncertainties of preliminary data and the extensive risk profile, a 'hold' recommendation is prudent until the full audited results are released and a more complete picture of the company's financial health and risk mitigation strategies can be assessed.

Keywords

Inotiv, NOTV, Preliminary Results, Q4 2025, FY 2025, Revenue, Contract Research Organization, CRO, Drug Discovery, Drug Development, Nonclinical Services, Analytical Services, Research Models, Book-to-bill, Backlog, Financial Performance, Biotechnology, Pharmaceuticals